MVRIX Co., Ltd. has closed a $6.1M Series B round, bringing in a syndicate of backers that includes Korea Investment Partners, InterVest, iGene, Korea Omega Investment, Lifecore Partners, and Seoul Techno Holdings.
The biotech company is developing its Navibody platform, which aims to enable precision-targeted delivery of mRNA therapeutics for applications like cancer and in vivo CAR-T. It also works on engineerable recombinant botulinum toxin and virucidal therapeutics. The fresh capital arrives as the company looks to push its platform technologies forward, though specific use-of-funds details were not disclosed.


.png&w=3840&q=75)














